Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 55

1.

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.

Brufsky AM.

Breast Cancer (Auckl). 2014 Jul 29;8:109-18. doi: 10.4137/BCBCR.S9453. eCollection 2014. Review.

PMID:
25125981
[PubMed]
Free PMC Article
2.

Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.

Chen J, Shao R, Li L, Xu ZP, Gu W.

Int J Nanomedicine. 2014 Jul 16;9:3403-11. doi: 10.2147/IJN.S61633. eCollection 2014.

PMID:
25075187
[PubMed - in process]
Free PMC Article
3.

Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops.

von Manstein V, Yang CM, Richter D, Delis N, Vafaizadeh V, Groner B.

Curr Signal Transduct Ther. 2013 Dec;8(3):193-202.

PMID:
25045345
[PubMed]
Free PMC Article
4.

Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.

Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA, Rouse MB, Rabindran SK, Heerding DA, Kumar R.

PLoS One. 2014 Jun 30;9(6):e100880. doi: 10.1371/journal.pone.0100880. eCollection 2014.

PMID:
24978597
[PubMed - in process]
Free PMC Article
5.

Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.

Glaysher S, Bolton LM, Johnson P, Torrance C, Cree IA.

BMC Res Notes. 2014 Jun 25;7:397. doi: 10.1186/1756-0500-7-397.

PMID:
24964744
[PubMed - in process]
Free PMC Article
6.

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.

Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL.

Breast Cancer Res. 2014 Jan 23;16(1):R9. doi: 10.1186/bcr3601.

PMID:
24451154
[PubMed - in process]
Free PMC Article
7.

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S, Rosen N.

Cancer Discov. 2014 Mar;4(3):334-47. doi: 10.1158/2159-8290.CD-13-0611. Epub 2014 Jan 16.

PMID:
24436048
[PubMed - in process]
Free PMC Article
8.

Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.

Tessari A, Palmieri D, Di Cosimo S.

Pharmgenomics Pers Med. 2013 Dec 16;7:1-19. doi: 10.2147/PGPM.S53304. Review.

PMID:
24403841
[PubMed]
Free PMC Article
9.

Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.

Guilbert C, Annis MG, Dong Z, Siegel PM, Miller WH Jr, Mann KK.

PLoS One. 2013 Dec 31;8(12):e85995. doi: 10.1371/journal.pone.0085995. eCollection 2013.

PMID:
24392034
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.

Toulany M, Minjgee M, Saki M, Holler M, Meier F, Eicheler W, Rodemann HP.

Cancer Biol Ther. 2014 Mar 1;15(3):317-28. doi: 10.4161/cbt.27311. Epub 2013 Dec 9.

PMID:
24351425
[PubMed - in process]
Free PMC Article
11.

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, Benes CH, Engelman JA.

Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9. doi: 10.1073/pnas.1314124110. Epub 2013 Dec 10.

PMID:
24327733
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.

Seemann I, te Poele JA, Song JY, Hoving S, Russell NS, Stewart FA.

Breast Cancer Res Treat. 2013 Oct;141(3):385-95. doi: 10.1007/s10549-013-2707-7. Epub 2013 Oct 4.

PMID:
24091769
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.

Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, Newton A, Fuchs EM, Paquet A, Singer CF, Horvat R, Jin X, Banerjee J, Mukherjee A, Tan Y, Shi Y, Chenna A, Larson J, Lie Y, Sherwood T, Petropoulos CJ, Williams S, Winslow J, Parry G, Bates M.

Breast Cancer Res Treat. 2013 Aug;141(1):43-53.

PMID:
23959396
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Lung cancer cells that survive ionizing radiation show increased integrin α2β1- and EGFR-dependent invasiveness.

Li X, Ishihara S, Yasuda M, Nishioka T, Mizutani T, Ishikawa M, Kawabata K, Shirato H, Haga H.

PLoS One. 2013 Aug 8;8(8):e70905. doi: 10.1371/journal.pone.0070905. eCollection 2013.

PMID:
23951036
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.

Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.

Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14372-7. doi: 10.1073/pnas.1303204110. Epub 2013 Aug 12.

PMID:
23940356
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice.

Watson KL, Moorehead RA.

BMC Cancer. 2013 Aug 7;13:375. doi: 10.1186/1471-2407-13-375.

PMID:
23919516
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.

Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, Eccles SA, Ruddle RR, Johnson LD, Raynaud FI, Selfe JL, Thway K, Pietsch T, Pearson AD, Shipley J.

Clin Cancer Res. 2013 Nov 1;19(21):5940-51. doi: 10.1158/1078-0432.CCR-13-0850. Epub 2013 Aug 5.

PMID:
23918606
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.

Chung A, Cui X, Audeh W, Giuliano A.

Clin Breast Cancer. 2013 Aug;13(4):223-32. doi: 10.1016/j.clbc.2013.04.001. Review.

PMID:
23829888
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

mTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss.

Ghosh S, Varela L, Sood A, Park BH, Lotan TL.

Cancer Res. 2013 Aug 15;73(16):5218-31. doi: 10.1158/0008-5472.CAN-13-0429. Epub 2013 Jun 17.

PMID:
23774212
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.

Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, Turner NC.

Cancer Discov. 2013 Sep;3(9):1058-71. doi: 10.1158/2159-8290.CD-12-0569. Epub 2013 Jun 6.

PMID:
23744832
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk